Text Size

Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by Sykehuset Innlandet HF.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Sykehuset Innlandet HF
ClinicalTrials.gov Identifier:
NCT01318174
First received: March 17, 2011
Last updated: April 14, 2011
Last verified: February 2011
History of Changes
  Purpose

The purpose of this study is to determine the prevalence of pulmonary embolism in our population of Chronic Obstructive Pulmonary Disease (COPD) patients admitted to hospital with dyspnea. The patients will undergo investigation for pulmonary embolism, according to current guidelines.


Condition
Pulmonary Embolism
Chronic Obstructive Pulmonary Disease

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Prevalence of Pulmonary Embolism in Exacerbations of Chronic Obstructive Pulmonary Disease

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Sykehuset Innlandet HF:

Estimated Enrollment: 100
Study Start Date: April 2011
Estimated Study Completion Date: April 2012
Estimated Primary Completion Date: April 2012 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with known or suspected COPD admitted with an exacerbation of unknown aetiology

Criteria

Inclusion Criteria:

  • known or suspected COPD
  • COPD-exacerbation

Exclusion Criteria:

  • other causes of dyspnea
  • unable to perform CT pulmonary angio (contrast allergy, pregnancy)
  • already included in the study (each patient included only once)
  • use of anticoagulants
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01318174

Contacts
Contact: Aleksander T Holten, PhD +47 48018363 aleksander.holten@sykehuset-innlandet.no

Locations
Norway
Sykehuset Innlandet Recruiting
Lillehammer, Oppland, Norway, 2381
Contact: Aleksander T Holten, PhD     +47 48018363     aleksander.holten@sykehuset-innlandet.no    
Sponsors and Collaborators
Sykehuset Innlandet HF
Investigators
Principal Investigator: Aleksander T Holten, PhD Sykehuset Innlandet HF
  More Information

No publications provided

Responsible Party: Aleksander Talgøy Holten, PhD, MD, Sykehuset Innlandet HF
ClinicalTrials.gov Identifier: NCT01318174     History of Changes
Other Study ID Numbers: LE-KE
Study First Received: March 17, 2011
Last Updated: April 14, 2011
Health Authority: Norway: Regional Ethics Commitee

Keywords provided by Sykehuset Innlandet HF:
Pulmonary embolism
Pulmonary Disease, Chronic Obstructive

Additional relevant MeSH terms:
Embolism
Lung Diseases
Respiration Disorders
Pulmonary Disease, Chronic Obstructive
Pulmonary Embolism
 Lung Diseases, Obstructive
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on May 19, 2013